Previously, it has been reported that CX-5461 treatment leads to varying consequences in cell cycle progression that correlate with p53 status: (i) p53 wild-type cancers: G1-phase cell cycle arrest [19,36]; (ii) p53 mutant cancers: G2-phase cell cycle arrest [36]. Here, TP53 is linked to cancer.